Skip to main content
micro-community-banner
 
  • Saved

made a Post

Anti-breast cancer drugs targeting cell-surface glucose-regulated protein 78: a drug repositioning in silico study - PubMed

Breast cancer (BC) is prevalent worldwide and is a leading cause of death among women. However, cell-surface glucose-regulated protein 78 (cs-GRP78) is overexpressed in several types of cancer and during ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36129131/


Conclusion: These findings demonstrate the efficacy of abemaciclib, ribociclib, and tunicamycin in binding to the nucleotide-binding domain of the GRP78, paving the way for elucidating the mode of interactions between these drugs and cancer (and other stressed) cells that overexpress GRP78.

  • Saved

made a Post

Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer | Miyahara | World Journal of Oncology

Kana Miyahara, Kazutaka Narui, Yukari Uemura, Akimitsu Yamada, Kazuhiro Araki, Fumie Fujisawa, Takahiro Nakayama, Takashi Ishikawa, Naruto Taira, Yuichiro Kikawa, Tomohiko Aihara, Hirofumi Mukai Abstract Background: Combination therapy with cyclin-dependent ..... see more

Source : https://www.wjon.org/index.php/WJON/article/view/1511


Discussion: In this multi-institutional prospective cohort study, we evaluate the clinical efficacy and safety of combination therapy with abemaciclib and hormonal therapy for chemotherapy-treated patients with HR HER2- MBC. We also evaluate this combination therapy as maintenance therapy in patients who respond to early-line chemotherapy.

  • Saved

made a Post

Breast Cancer and Secondary Cancer Recurrences After Autologous Tissue Reconstruction

Micro-AbstractA 20-year retrospective review of locoregional recurrences, secondary cancers, and atypical breast neoplasms after autologous tissue reconstruction for cancer of the breast identified an overall recurrence rate of 5.3%. The ..... see more

Source : https://www.clinical-breast-cancer.com/article/S1526-8209(20)30181-6/fulltext


Conclusion: Our retrospective review found incidence and survival after treatment of breast cancer concordant with reports in the literature. We also identified and analyzed secondary neoplasms, including a unique case of undifferentiated pleomorphic sarcoma and metachronous recurrence of breast carcinoma. A case of recurrence as metaplastic...

  • Saved

made a Post

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study - PubMed

1 Department of Biology and Biochemistry, University of Bath, Bath BA2 7 AY, UK. 2 Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, 91190 Gif-sur-Yvette, France. 3 Department of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36135204/


Conclusions: Our study strongly supports the notion that CDK4/6 inhibitors induce tumour immune modulation. N/L ratio and platelet levels decreased due to treatment. Future studies should test whether patients would benefit from immunomodulators in association with CDK4/6 agents in a larger clinical trial. Moreover, the CDK4/6-induced immune...

  • Saved

Commented on 's Post

Bias Against International Medical Graduates in the Hematology/Oncology Fellowship Recruitment Process: Findings From a Nationwide Survey of Fellowship Program Directors

One quarter of all practicing physicians in the United States and over one third of all US hematologists and oncologists are international medical graduates (IMGs). IMGs are defined as physicians ..... see more

Source : https://ascopubs.org/doi/full/10.1200/OP.22.00219


Relevance: One quarter of all practicing physicians in the United States and over one third of all US hematologists and oncologists are international medical graduates (IMGs). IMGs are defined as physicians who have graduated from a medical school outside the United States and Canada, a population that includes US citizens and permanent...

Show More Comments

  • Saved

Commented on 's Post

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

BackgroundUpdated evidence was required to compare the efficacy and safety of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) inhibitors ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.956464/full


Conclusions: CDK4/6 inhibitors showed better efficacy in PFS, but the benefits disappeared when taking treatment line into consideration. Specific and discrepant safety profiles were found in two categories of agents.

Show More Comments

  • September 25, 2022
    this very interesting and rather intriguing. In my mind patients should get either one depending on particular circumstances
  • Saved

made a Post

An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low) - PubMed

doi: 10.1001/jamaoncol.2022.4175. Online ahead of print. 1 Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. 2 Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36107417/


Conclusions and Relevance: This review suggests that ERBB2-low may be a distinct, clinically relevant breast cancer entity warranting reassessment of traditional diagnostic and therapeutic paradigms. Ongoing clinical trials and further investigations may provide optimized strategies for diagnosing and treating ERBB2-low breast cancer,...

  • Saved

made a Post

Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib - PubMed

These real-world data complement clinical trial results by examining abemaciclib use among patients treated in routine clinical practice. The sizeable number of patients treated with prior CDK4 & 6i, chemotherapy, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36097254/


Conclusion: These real-world data complement clinical trial results by examining abemaciclib use among patients treated in routine clinical practice. The sizeable number of patients treated with prior CDK4 & 6i, chemotherapy, and/or visceral metastases at abemaciclib initiation suggest that many patients had very advanced disease and/or were in...

  • Saved

Commented on 's Post

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights

Providing evidence that there was no loss of efficacy by administering chemotherapy before surgery enabled investigators to exploit the huge translational research opportunities of the neoadjuvant setting. This in turn ..... see more

Source : https://www.dovepress.com/optimal-choice-of-neoadjuvant-chemotherapy-for-her2-negative-breast-ca-peer-reviewed-fulltext-article-CMAR


Relevance: In this article we review neoadjuvant clinical trials that guide optimum treatment options for TNBC and HR-positive, HER2-negative breast cancer.

Show More Comments

  • September 13, 2022
    Thanks for your input, Albert Dekker ! What new treatments do others suggest for TNBC and HR-positive, HER2-negative breast cancer?
  • September 09, 2022
    few compared newer agents against one the other
  • Saved

made a Post

Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer

PURPOSE Despite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with ..... see more

Source : https://ascopubs.org/doi/10.1200/JCO.22.00083


Conclusion: Medication-naïve stage 1 and 2 hypertension was associated with a greater risk of HF and other CVD events in patients with cancer. Our results suggest the importance of multidisciplinary collaboration (eg, oncologists and cardiologists) to establish the optimal management strategy for hypertension in patients with cancer.

  • Saved

made a Post

Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models

Cyclin-dependent kinases, CDK4 and CDK6, are essential in regulating the cell cycle, which is disrupted in cancers like isocitrate dehydrogenase wild-type glioblastoma (GBM). Currently marketed CDK4/6 inhibitors, including abemaciclib, have ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.915862/full


Conclusion/Relevance: These studies show possible BBB penetration of GLR2007 and demonstrate its potential as a CDK4/6 inhibitor for the treatment of solid tumors, including GBM.

  • Saved

made a Post

KIFC1: A Reliable Prognostic Biomarker in Rb-positive Triple-negative Breast Cancer Patients Treated With Doxorubicin in Combination With Abemaciclib

Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype characterized by the lack of the three hallmark receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor ..... see more

Source : https://www.cancerdiagnosisprognosis.org/?p=2485


Conclusion:Change in KIFC1 expression is primarily driven by ABE in Rb-positive TNBC cells. DOX increases ABE speed to achieve a full inhibition of KIFC1 in Rb-positive, yet, without influencing its expression in Rb-negative TNBC cells.

  • Saved

made a Post

Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget's Disease

Published systemic therapy options for metastatic extramammary Paget's disease have largely been anecdotal due to the rarity of this disease, which has precluded the ability to conduct clinical trials. We ..... see more

Source : https://www.cureus.com/articles/106769-efficacy-of-abemaciclib-in-the-management-of-refractory-metastatic-extramammary-pagets-disease


Relevance: Published systemic therapy options for metastatic extramammary Paget's disease have largely been anecdotal due to the rarity of this disease, which has precluded the ability to conduct clinical trials. We describe the favorable response of a 72-year-old man with extramammary Paget's disease, whose disease has been controlled with the...

  • Saved

Commented on 's Post

Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA) - PubMed

The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36005450/


Conclusion/Relevance: Our study is the first to capture real-world data on the use of pertuzumab in the neoadjuvant setting in Australia. The effectiveness and safety data are consistent with those reported in clinical trials of pertuzumab in patients with HER2 breast cancer, with no new safety concerns.

Show More Comments

  • September 09, 2022
    not sure how relevant that is for US. This is clearly example that socialized medicine is at least 5 year behind
  • Saved

Commented on 's Post

Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer

Palbociclib, ribociclib and abemaciclib are selective CDK4/6 inhibitors, approved for HR+, HER2-, advanced or metastatic breast cancer * Various mechanisms of primary ( de novo) or acquired resistance to CDK4/6 ..... see more

Source : https://www.sciencedirect.com/science/article/abs/pii/S0167488922001380?via=ihub


Relevance: This review presents the currently available knowledge on the mechanisms of resistance to CDK4/6 inhibitors, explores possible treatment strategies that could overcome this therapeutic problem, and summarizes relevant recent clinical trials.

Show More Comments

  • September 09, 2022
    clearly not sufficient for this important class of agents
  • September 07, 2022
    Key Points • Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell Research • Conclusion/Relevance: “This review presents the currently available knowledge on the mechanisms of resistance to CDK4/6 inhibitors, explores possible treatment strategies Show More
  • Saved

made a Post

Steviol glycosides affect functional properties and macromolecular expression of breast cancer cells - PubMed

Steviol glycosides, the active sweet components of stevia plant, have been recently found to possess a number of therapeutic properties, including some recorded anticancer ones against various cancer cell types ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36054915/


Conclusion: The above data clearly demonstrate that steviol glycosides have different effects on breast cancer cells according to their ER status, suggesting that steviol glycosides might be examined for their potential anticancer activity against breast cancer, especially triple negative breast cancer (TNBC).

  • Saved

made a Post

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review) - PubMed

In recent years, the incidence rate of breast cancer has increased year by year, and it has become a major threat to the health of women globally. Among all breast ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36043521/


Conclusion/Relevance: With the discovery of the drug resistance mechanism of CDK4/6 inhibitors, various targeted strategies have been proposed. The present review mainly discusses the mechanism of CDK4/6 inhibitors, drug resistance mechanisms and treatment strategies after resistance.

  • Saved

made a Post

CD39 + tissue-resident memory CD8 + T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer - PubMed

Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors (ICIs) are only efficacious for a subset of patients. To gain a better understanding of the antitumor immune ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36026440/


Conclusion: Our study indicates that CD39 TRM cells with a clonal overlap across compartments are key players in antitumor immunity in breast cancer.